Deudomperidone

Today, Deudomperidone is a topic that generates great interest and debate in society. Its relevance has been increasing in recent years, covering various areas such as technology, culture, politics and science. Deudomperidone has managed to capture the attention of experts and fans, as well as citizens in general, becoming a fundamental part of the media and social agenda. In this article, we will explore in depth the different aspects and facets related to Deudomperidone, with the aim of offering a comprehensive and updated vision on this topic of great importance today.

Deudomperidone
Clinical data
Other namesCIN-102; deuterated domperidone; domperidone deuterated
Identifiers
  • 3-propyl]-4,5,6,7-tetradeuterio-1H-benzimidazol-2-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H20ClD4N5O2
Molar mass429.94 g·mol−1
3D model (JSmol)
  • C1=C(C(=C2C(=C1)NC(=O)N2CCCN3CCC(CC3)N4C5=C(C=C(C=C5)Cl)NC4=O))
  • InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)/i1D,2D,4D,5D
  • Key:FGXWKSZFVQUSTL-GYABSUSNSA-N

Deudomperidone (developmental code name CIN-102; also known as deuterated domperidone) is a dopamine antagonist medication which is under development in the United States for the treatment of gastroparesis.[1][2][3] It acts as a selective dopamine D2 and D3 receptor antagonist and has peripheral selectivity.[2][3] Deudomperidone is a deuterated form of domperidone, and it is suggested that deudomperidone may have improved efficacy, tolerability, and pharmacokinetics compared to domperidone.[2][3] As of January 2022, deudomperidone is in phase 2 clinical trials for the treatment of gastroparesis.[1]

See also

References

  1. ^ a b "Deudomperidone - CinRx Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ a b c Heckroth M, Luckett RT, Moser C, Parajuli D, Abell TL (April 2021). "Nausea and Vomiting in 2021: A Comprehensive Update". Journal of Clinical Gastroenterology. 55 (4): 279–299. doi:10.1097/MCG.0000000000001485. PMC 7933092. PMID 33471485.
  3. ^ a b c Wo JM, McCallum RW, Gonzalez Z (2021). "Antiemetic therapy for gastroparesis". In McCallum RW, Parkman HP (eds.). Gastroparesis. Elsevier. pp. 341–359. doi:10.1016/B978-0-12-818586-5.00025-9. ISBN 9780128185865. S2CID 225132800.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.